This study is the first to explore whether TQ could target the aforementioned pro-tumorigenic BC markers, which consist of the CALR, NLRP3 pathway with a focus on the downstream IL-1β expression and protein release in both PBMCs and TAMs isolated from TNBC and HR+ BC patients, respectively. This evidence concerns the gene CALR and breast cancer.